Achieve Life Sciences (ACHV) Accumulated Depreciation (2012 - 2020)
Achieve Life Sciences' (ACHV) quarterly Accumulated Depreciation came in at $632000.0 in Q4 2020, up 5.33% YoY from $600000.0 in Q1 2020, and up 5.33% on a QoQ basis from $600000.0 in Q4 2019.
Achieve Life Sciences (ACHV) Accumulated Depreciation (2012 - 2020) Analysis & Trends
Achieve Life Sciences (ACHV) has 9 years of Accumulated Depreciation data on file, last reported at $632000.0 in Q4 2020.
- Quarterly Accumulated Depreciation rose 5.33% year-over-year to $632000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $632000.0 (up 5.33% YoY) and the FY2020 annual result came in at $632000.0, up 5.33% from the prior year.
- Accumulated Depreciation advanced to $632000.0 in Q4 2020, from $600000.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $1.4 million in Q4 2016 to a low of $600000.0 in Q4 2019.
- A 5-year average of $897200.0 and a median of $720000.0 in 2018 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2016 — Accumulated Depreciation grew 13.11% — and 2018, when it slumped 33.64%.
- Tracing ACHV's Accumulated Depreciation over 5 years: stood at $1.4 million in 2016, then retreated by 25.12% to $1.1 million in 2017, then tumbled by 33.64% to $720000.0 in 2018, then fell by 16.67% to $600000.0 in 2019, then increased by 5.33% to $632000.0 in 2020.
- The last three Accumulated Depreciation figures came in at $632000.0 (Q4 2020), $600000.0 (Q4 2019), and $720000.0 (Q4 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 632,000.00 |
| Dec 31, 2019 | 600,000.00 |
| Dec 31, 2018 | 720,000.00 |
| Dec 31, 2017 | 1.09 Mn |
| Dec 31, 2016 | 1.45 Mn |
| Dec 31, 2015 | 1.28 Mn |
| Dec 31, 2014 | 1.04 Mn |
| Dec 31, 2013 | 814,000.00 |
| Dec 31, 2012 | 604,000.00 |